Showing 1 - 20 results of 80 for search '"TNBC"', query time: 0.07s Refine Results
  1. 1
  2. 2

    A select inhibitor of MORC2 encapsulated by chimeric membranecoated DNA nanocage target alleviation TNBC progression by Xiaohan Su, Yunbo Luo, Yali Wang, Peng Qu, Jun Liu, Shiqi Han, Cui Ma, Shishan Deng, Qi Liang, Xiaowei Qi, Panke Cheng, Lingmi Hou

    Published 2025-04-01
    “…In this study, bioinformatic analysis and a series of experiments demonstrated that MOCR2 was highly expressed in TNBC and closely associated with poor prognosis, indicating that MOCR2 may be a potential therapeutic target for TNBC. …”
    Get full text
    Article
  3. 3
  4. 4

    Anti-TNBC effects of Lappaol F by targeting epithelial-mesenchymal transition via regulation of GSK-3β/YAP/β-catenin and PI3K/AKT pathways by Qiqi Meng, Qiqi Meng, Zhiping Li, Xiaofeng He, Yuanhao Hu, Guiyun Wu, Jiawen Huang, Zhuohui Luo, Zhuohui Luo, Yingjie Hu, Xiaoling Shen

    Published 2025-02-01
    “…PurposeLappaol F (LAF), a lignan extracted from Fructus Arctii, has a wide spectrum of anti-tumor effects, including inhibition of TNBC cell growth. However, the pharmacological mechanism of LAF targeting epithelial-mesenchymal transition (EMT) to inhibit Triple-negative breast cancer (TNBC) growth remains poorly understood. …”
    Get full text
    Article
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16

    Clinical Characteristics in Patients with Triple Negative Breast Cancer by Janet Yeh, Jennifer Chun, Shira Schwartz, Annie Wang, Elizabeth Kern, Amber A. Guth, Deborah Axelrod, Richard Shapiro, Freya Schnabel

    Published 2017-01-01
    “…The purpose of this study was to compare and contrast the clinical characteristics of the triple negative breast cancer (TNBC) and non-TNBC patients, with a particular focus on genetic susceptibility and risk factors prior to diagnosis. …”
    Get full text
    Article
  17. 17

    Mechanistic insights into pachymic acid’s action on triple-negative breast Cancer through TOP2A targeting by Ming Liu, Li Zheng, Yang Zhang, Jinhui Tian

    Published 2025-01-01
    “…The therapeutic effects of PA may vary across different subtypes of TNBC such as TNBC-BL1, TNBC-Metaplastic, and TNBC-BL2. …”
    Get full text
    Article
  18. 18

    Clinicopathological and Prognostic Characteristics of Malaysian Triple Negative Breast Cancer Patients Undergoing TAC Chemotherapy Regimen by Ahmad Aizat Abdul Aziz, Md Salzihan Md Salleh, Ravindran Ankathil

    Published 2020-01-01
    “…Triple negative breast cancer (TNBC) is associated with aggressive tumour phenotype and early tumour relapse following diagnosis. …”
    Get full text
    Article
  19. 19

    SHP2 promotes the epithelial-mesenchymal transition in triple negative breast cancer cells by regulating β-catenin by Shihan Qian, Jingjing Zhu, Qing Han, Huang Cheng, Huaibin Zhou

    Published 2025-01-01
    “…Results We found that high SHP2 expression was associated with a poor prognosis in patients with TNBC. The migratory and invasive abilities of TNBC cells in vitro, as well as the metastatic potential of TNBC in mouse xenograft models, were reduced after SHP2 depletion. …”
    Get full text
    Article
  20. 20

    Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality by Noor A. M. Bakker, Hannah Garner, Ewald van Dyk, Elisa Champanhet, Chris Klaver, Maxime Duijst, Leonie Voorwerk, Iris Nederlof, Rosie Voorthuis, Marte C. Liefaard, Marja Nieuwland, Iris de Rink, Onno B. Bleijerveld, Hendrika M. Oosterkamp, Lodewyk F. A. Wessels, Marleen Kok, Karin E. de Visser

    Published 2025-01-01
    “…We profiled circulating immune cells in stage I–III and stage IV triple-negative breast cancer (TNBC) patients and healthy donors (HDs). Metastatic TNBC (mTNBC) patients had reduced T cells, dendritic cells, and differentiated B cells compared to non-metastatic TNBC patients and HDs, partly linked to prior chemotherapy. …”
    Get full text
    Article